Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation

Gene therapy approaches delivering fibroblast growth factor-2 (FGF-2) have shown promise as a potential treatment for increasing blood flow to ischemic limbs. Currently, effective noninvasive techniques to deliver plasmids encoding genes of therapeutic interest, such as FGF-2, are limited. We sought to determine if intradermal injection of plasmid DNA encoding FGF-2 (pFGF) followed by noninvasive cutaneous electroporation (pFGFE+) could increase blood flow and angiogenesis in a rat model of hindlimb ischemia. pFGFE+ or control treatments were administered on postoperative day 0. Compared to injection of pFGF alone (pFGFE−), delivery of pFGFE+ significantly increased FGF-2 expression for 10 days. Further, the increase in FGF-2 expression with pFGFE+ was sufficient to significantly increase ischemic limb blood flow, measured by laser Doppler perfusion imaging, beginning on postoperative day 3. Ischemic limb blood flow in the pFGFE+ treatment group remained significantly higher than all control groups through the end point of the study, postoperative day 14. Immunohistochemical staining of gastrocnemius cross sections determined there was a twofold increase in capillary density in the pFGFE+ treatment group. Our results suggest that pFGFE+ is a potential noninvasive, nonviral therapeutic approach to increase perfusion and angiogenesis for the treatment of limb ischemia.

[1]  A. Quyyumi,et al.  Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. , 2000, Journal of the American College of Cardiology.

[2]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[3]  Y. Itoyama,et al.  EFFECT OF LOW‐VOLTAGE ELECTRICAL STIMULATION ON ANGIOGENIC GROWTH FACTORS IN ISCHAEMIC RAT SKELETAL MUSCLE , 2006, Clinical and experimental pharmacology & physiology.

[4]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[5]  Véronique Préat,et al.  Topical Gene Transfer into Rat Skin Using Electroporation , 2004, Pharmaceutical Research.

[6]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[7]  D. Hanahan,et al.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.

[8]  A. Gardner,et al.  Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. , 1995, JAMA.

[9]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[10]  J. Vogel,et al.  Nonviral skin gene therapy. , 2000, Human gene therapy.

[11]  Y. Tabata,et al.  A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[12]  Y. Taniyama,et al.  Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model: Molecular Mechanisms of Delayed Angiogenesis in Diabetes , 2001, Circulation.

[13]  R. Oostendorp,et al.  Exercise therapy for intermittent claudication: a review of the quality of randomised clinical trials and evaluation of predictive factors. , 1998, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[14]  Richard Heller,et al.  Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array. , 2010, Human gene therapy.

[15]  R. Malone,et al.  Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  S. Ylä-Herttuala,et al.  Therapeutic angiogenesis with placental growth factor improves exercise tolerance of ischaemic rabbit hindlimbs. , 2008, Cardiovascular research.

[17]  L. Cooper,et al.  Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication , 2001, Vascular medicine.

[18]  R. Malone,et al.  Efficient nonviral cutaneous transfection. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[19]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[20]  V. Bobek,et al.  Gene therapy of the ischemic lower limb--Therapeutic angiogenesis. , 2006, Vascular pharmacology.

[21]  Huafeng Zhang,et al.  Age‐dependent impairment of HIF‐1α expression in diabetic mice: Correction with electroporation‐facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells , 2008, Journal of cellular physiology.

[22]  E. Jeon,et al.  Combined administration of naked DNA vectors encoding VEGF and bFGF enhances tissue perfusion and arteriogenesis in ischemic hindlimb. , 2007, Biochemical and biophysical research communications.

[23]  K. Sugimachi,et al.  Angiogenic Gene Therapy for Experimental Critical Limb Ischemia: Acceleration of Limb Loss by Overexpression of Vascular Endothelial Growth Factor 165 but not of Fibroblast Growth Factor-2 , 2002, Circulation research.

[24]  T. Fujii,et al.  VEGF function for upregulation of endogenous PlGF expression during FGF-2-mediated therapeutic angiogenesis. , 2008, Atherosclerosis.

[25]  John V. White,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[26]  Jagdish Singh,et al.  Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. , 2005, International journal of pharmaceutics.

[27]  Leaf Huang,et al.  Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. , 2004, The Journal of investigative dermatology.

[28]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[29]  S. Kanno,et al.  Establishment of a simple and practical procedure applicable to therapeutic angiogenesis. , 1999, Circulation.

[30]  J. Miyazaki,et al.  Skin-targeted gene transfer using in vivo electroporation , 2001, Gene Therapy.

[31]  Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[32]  M. Jaroszeski,et al.  Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. , 2001, DNA and cell biology.

[33]  R. Lederman,et al.  Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF‐2) , 2003, British journal of pharmacology.

[34]  C. Yoshizawa,et al.  Pharmacokinetics and Pharmacodynamics of Recombinant FGF‐2 in a Phase I Trial in Coronary Artery Disease , 2001, Journal of clinical pharmacology.

[35]  G. Marti,et al.  Delivery of plasmid DNA expression vector for keratinocyte growth factor‐1 using electroporation to improve cutaneous wound healing in a septic rat model , 2006, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[36]  J. Angus,et al.  Vascular Effects of FGF-2 and VEGF-B in Rabbits with Bilateral Hind Limb Ischemia , 2008, Journal of Vascular Research.

[37]  S. Ylä-Herttuala,et al.  Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb – on the way to the clinic , 2001, European journal of clinical investigation.

[38]  Armin Helisch,et al.  Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. , 2002, Journal of molecular and cellular cardiology.

[39]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[40]  T. Miyata,et al.  In vivo electroporation enhances plasmid-based gene transfer of basic fibroblast growth factor for the treatment of ischemic limb. , 2004, The Journal of surgical research.

[41]  K. Nakagawa,et al.  Fibroblast Growth Factor-2 Gene Transfer Can Stimulate Hepatocyte Growth Factor Expression Irrespective of Hypoxia-Mediated Downregulation in Ischemic Limbs , 2002, Circulation research.

[42]  K. Alitalo,et al.  Gene transfer as a tool to induce therapeutic vascular growth , 2003, Nature Medicine.

[43]  D. Weiner,et al.  Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. , 2008, Vaccine.

[44]  G. Marti,et al.  Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model , 2004, Gene Therapy.

[45]  T. VandenDriessche,et al.  Xenogeneic liver models for gene therapy. , 2010, Human gene therapy.

[46]  J. Hooper,et al.  Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge , 2006, Vaccine.

[47]  L. Babiuk,et al.  Electroporation improves the efficacy of DNA vaccines in large animals. , 2002, Vaccine.

[48]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.